A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Abstract Background Chronic cyclic pelvic pain (CCPP) affects women’s quality of life and pituitary downregulation is often used for symptomatic relief. However, prolonged suppression of ovarian function is associated with menopausal side effects and can lead to osteoporosis. Currently, the use of g...

Full description

Bibliographic Details
Main Authors: Sallwa M. Alshehre, Sheila Duffy, Georgina Jones, William L. Ledger, Mostafa Metwally
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Reproductive Biology and Endocrinology
Subjects:
Endometriosis
Chronic cyclic pelvic pain
GnRH
Add back therapy
Online Access:http://link.springer.com/article/10.1186/s12958-020-00586-z

Internet

http://link.springer.com/article/10.1186/s12958-020-00586-z

Similar Items